United States Abbott Laboratories (ABT): Financial Data Breakdowns & Operational Data
United States US: ABT: Number of Employee
US: ABT: No of Employee data was reported at 99,000.000 Person in 2017. This records an increase from the previous number of 75,000.000 Person for 2016. US: ABT: No of Employee data is updated yearly, averaging 75,000.000 Person from Dec 2007 (Median) to 2017, with 11 observations. The data reached an all-time high of 99,000.000 Person in 2017 and a record low of 68,697.000 Person in 2007. US: ABT: No of Employee data remains active status in CEIC and is reported by Abbott Laboratories. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Abbott Laboratories (ABT): Financial Data Breakdowns & Operational Data.
| Last | Frequency | Range |
|---|---|---|
| 99,000.00 2017 | yearly | 2007 - 2017 |
View United States's United States US: ABT: Number of Employee from 2007 to 2017 in the chart:
United States US: ABT: Operating Profit: Cardiovascular and Neuromodulation Products
US: ABT: Operating Profit: Cardiovascular and Neuromodulation Products data was reported at 724,000.000 USD th in Mar 2018. This records a decrease from the previous number of 2,720,000.000 USD th for Dec 2017. US: ABT: Operating Profit: Cardiovascular and Neuromodulation Products data is updated quarterly, averaging 786,000.000 USD th from Mar 2016 (Median) to Mar 2018, with 9 observations. The data reached an all-time high of 2,720,000.000 USD th in Dec 2017 and a record low of 247,000.000 USD th in Mar 2016. US: ABT: Operating Profit: Cardiovascular and Neuromodulation Products data remains active status in CEIC and is reported by Abbott Laboratories. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Abbott Laboratories (ABT): Financial Data Breakdowns & Operational Data.
| Last | Frequency | Range |
|---|---|---|
| 724,000.00 Mar 2018 | quarterly | Mar 2016 - Mar 2018 |
View United States's United States US: ABT: Operating Profit: Cardiovascular and Neuromodulation Products from Mar 2016 to Mar 2018 in the chart:
United States US: ABT: Operating Profit: Diagnostic Products
US: ABT: Operating Profit: Diagnostic Products data was reported at 443,000.000 USD th in Mar 2018. This records a decrease from the previous number of 1,468,000.000 USD th for Dec 2017. US: ABT: Operating Profit: Diagnostic Products data is updated quarterly, averaging 267,000.000 USD th from Dec 1999 (Median) to Mar 2018, with 73 observations. The data reached an all-time high of 1,468,000.000 USD th in Dec 2017 and a record low of 26,000.000 USD th in Mar 2007. US: ABT: Operating Profit: Diagnostic Products data remains active status in CEIC and is reported by Abbott Laboratories. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Abbott Laboratories (ABT): Financial Data Breakdowns & Operational Data.
| Last | Frequency | Range |
|---|---|---|
| 443,000.00 Mar 2018 | quarterly | Dec 1999 - Mar 2018 |
View United States's United States US: ABT: Operating Profit: Diagnostic Products from Dec 1999 to Mar 2018 in the chart:
United States US: ABT: Operating Profit: Established Pharmaceutical Product
US: ABT: Operating Profit: Established Pharmaceutical Product data was reported at 167,000.000 USD th in Mar 2018. This records a decrease from the previous number of 848,000.000 USD th for Dec 2017. US: ABT: Operating Profit: Established Pharmaceutical Product data is updated quarterly, averaging 523,500.000 USD th from Dec 2009 (Median) to Mar 2018, with 34 observations. The data reached an all-time high of 1,254,000.000 USD th in Dec 2011 and a record low of 121,000.000 USD th in Mar 2014. US: ABT: Operating Profit: Established Pharmaceutical Product data remains active status in CEIC and is reported by Abbott Laboratories. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Abbott Laboratories (ABT): Financial Data Breakdowns & Operational Data.
| Last | Frequency | Range |
|---|---|---|
| 167,000.00 Mar 2018 | quarterly | Dec 2009 - Mar 2018 |
View United States's United States US: ABT: Operating Profit: Established Pharmaceutical Product from Dec 2009 to Mar 2018 in the chart:
United States US: ABT: Operating Profit: Nutritional Products
US: ABT: Operating Profit: Nutritional Products data was reported at 365,000.000 USD th in Mar 2018. This records a decrease from the previous number of 1,589,000.000 USD th for Dec 2017. US: ABT: Operating Profit: Nutritional Products data is updated quarterly, averaging 644,000.000 USD th from Dec 2004 (Median) to Mar 2018, with 54 observations. The data reached an all-time high of 1,741,000.000 USD th in Dec 2015 and a record low of 155,000.000 USD th in Mar 2011. US: ABT: Operating Profit: Nutritional Products data remains active status in CEIC and is reported by Abbott Laboratories. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Abbott Laboratories (ABT): Financial Data Breakdowns & Operational Data.
| Last | Frequency | Range |
|---|---|---|
| 365,000.00 Mar 2018 | quarterly | Dec 2004 - Mar 2018 |
View United States's United States US: ABT: Operating Profit: Nutritional Products from Dec 2004 to Mar 2018 in the chart:
United States US: ABT: Research and Development Expense to Sales ratio
US: ABT: Research and Development Expense to Sales ratio data was reported at 8.200 % in 2017. This records an increase from the previous number of 6.800 % for 2016. US: ABT: Research and Development Expense to Sales ratio data is updated yearly, averaging 7.000 % from Dec 2007 (Median) to 2017, with 11 observations. The data reached an all-time high of 9.700 % in 2007 and a record low of 6.300 % in 2009. US: ABT: Research and Development Expense to Sales ratio data remains active status in CEIC and is reported by Abbott Laboratories. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Abbott Laboratories (ABT): Financial Data Breakdowns & Operational Data.
| Last | Frequency | Range |
|---|---|---|
| 8.20 2017 | yearly | 2007 - 2017 |
View United States's United States US: ABT: Research and Development Expense to Sales ratio from 2007 to 2017 in the chart:
United States US: ABT: Revenue (External): Cardiovascular and Neuromodulation Products
US: ABT: Revenue (External): Cardiovascular and Neuromodulation Products data was reported at 2,323,000.000 USD th in Mar 2018. This records a decrease from the previous number of 8,911,000.000 USD th for Dec 2017. US: ABT: Revenue (External): Cardiovascular and Neuromodulation Products data is updated quarterly, averaging 2,323,000.000 USD th from Mar 2016 (Median) to Mar 2018, with 9 observations. The data reached an all-time high of 8,911,000.000 USD th in Dec 2017 and a record low of 685,000.000 USD th in Mar 2016. US: ABT: Revenue (External): Cardiovascular and Neuromodulation Products data remains active status in CEIC and is reported by Abbott Laboratories. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Abbott Laboratories (ABT): Financial Data Breakdowns & Operational Data.
| Last | Frequency | Range |
|---|---|---|
| 2,323,000.00 Mar 2018 | quarterly | Mar 2016 - Mar 2018 |
View United States's United States US: ABT: Revenue (External): Cardiovascular and Neuromodulation Products from Mar 2016 to Mar 2018 in the chart:
United States US: ABT: Revenue (External): Diagnostic Products
US: ABT: Revenue (External): Diagnostic Products data was reported at 1,837,000.000 USD th in Mar 2018. This records a decrease from the previous number of 5,616,000.000 USD th for Dec 2017. US: ABT: Revenue (External): Diagnostic Products data is updated quarterly, averaging 2,235,000.000 USD th from Dec 1999 (Median) to Mar 2018, with 73 observations. The data reached an all-time high of 5,616,000.000 USD th in Dec 2017 and a record low of 679,000.000 USD th in Mar 2002. US: ABT: Revenue (External): Diagnostic Products data remains active status in CEIC and is reported by Abbott Laboratories. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Abbott Laboratories (ABT): Financial Data Breakdowns & Operational Data.
| Last | Frequency | Range |
|---|---|---|
| 1,837,000.00 Mar 2018 | quarterly | Dec 1999 - Mar 2018 |
View United States's United States US: ABT: Revenue (External): Diagnostic Products from Dec 1999 to Mar 2018 in the chart:
United States US: ABT: Revenue (External): Established Pharmaceutical Product
US: ABT: Revenue (External): Established Pharmaceutical Product data was reported at 1,044,000.000 USD th in Mar 2018. This records a decrease from the previous number of 4,287,000.000 USD th for Dec 2017. US: ABT: Revenue (External): Established Pharmaceutical Product data is updated quarterly, averaging 2,476,500.000 USD th from Dec 2009 (Median) to Mar 2018, with 34 observations. The data reached an all-time high of 5,355,000.000 USD th in Dec 2011 and a record low of 681,000.000 USD th in Mar 2014. US: ABT: Revenue (External): Established Pharmaceutical Product data remains active status in CEIC and is reported by Abbott Laboratories. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Abbott Laboratories (ABT): Financial Data Breakdowns & Operational Data.
| Last | Frequency | Range |
|---|---|---|
| 1,044,000.00 Mar 2018 | quarterly | Dec 2009 - Mar 2018 |
View United States's United States US: ABT: Revenue (External): Established Pharmaceutical Product from Dec 2009 to Mar 2018 in the chart:
United States US: ABT: Revenue (External): Nutritional Products
US: ABT: Revenue (External): Nutritional Products data was reported at 1,756,000.000 USD th in Mar 2018. This records a decrease from the previous number of 6,925,000.000 USD th for Dec 2017. US: ABT: Revenue (External): Nutritional Products data is updated quarterly, averaging 3,379,500.000 USD th from Dec 2004 (Median) to Mar 2018, with 54 observations. The data reached an all-time high of 6,975,000.000 USD th in Dec 2015 and a record low of 995,000.000 USD th in Mar 2005. US: ABT: Revenue (External): Nutritional Products data remains active status in CEIC and is reported by Abbott Laboratories. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Abbott Laboratories (ABT): Financial Data Breakdowns & Operational Data.
| Last | Frequency | Range |
|---|---|---|
| 1,756,000.00 Mar 2018 | quarterly | Dec 2004 - Mar 2018 |